Stock Scorer

Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Inc. reported revenue of 75.3M USD for the quarter ending 30 June 2026, up 171.0% from 27.8M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 75.3M +171.0%
Operating Income Q2 '26 · ending 30 June 2026 -170.1M —
Net Income Q2 '26 · ending 30 June 2026 -194.3M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -177.5M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -181.3M —
Shares Outstanding Q2 '26 · ending 30 June 2026 143.4M +6.6%
EPS Q2 '26 · ending 30 June 2026 -2.18 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-09-30 829.4M98.3M-1.6M156.9M
20242024-09-30 3.6M-601.1M-599.5M-604.3M
20232023-09-30 240.7M-205M-205.3M-330.6M
20222022-09-30 243.2M-178.5M-176.1M-188.9M
20212021-09-30 138.3M-149M-140.8M147.7M
20202020-09-30 88M-93.2M-84.6M-107.8M
20192019-09-30 168.8M61.2M68M161M
20182018-09-30 16.1M-55.9M-54.5M-48.6M
20172017-09-30 31.4M-37M-34.4M-31.9M
20162016-09-30 158.3K-81.7M-81.7M-68.3M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q3 '262026-06-3075.3M
Q2 '262026-03-3173.7M
Q1 '262025-12-31264M
Q4 '252025-09-30256.5M
Q3 '252025-06-3027.8M
Q2 '252025-03-31542.7M
Q1 '252024-12-312.5M
Q4 '242024-09-300
Q3 '242024-06-300
Q2 '242024-03-310
Q1 '242023-12-313.6M
Q4 '232023-09-3016.1M
Q3 '232023-06-3015.8M
Q2 '232023-03-31146.3M
Q1 '232022-12-3162.5M
Q4 '222022-09-3031.6M
Q3 '222022-06-3032.4M
Q2 '222022-03-31151.8M
Q1 '222021-12-3127.4M
Q4 '212021-09-3038.3M

Operating Income Quarterly

PeriodEndingOperating Income
Q3 '262026-06-30-170.1M
Q2 '262026-03-31-141.3M
Q1 '262025-12-3140.8M
Q4 '252025-09-3044.1M
Q3 '252025-06-30-165.6M
Q2 '252025-03-31381.2M
Q1 '252024-12-31-161.4M
Q4 '242024-09-30-162.2M
Q3 '242024-06-30-176.1M
Q2 '242024-03-31-126.2M
Q1 '242023-12-31-136.5M
Q4 '232023-09-30-108.3M
Q3 '232023-06-30-102.7M
Q2 '232023-03-3148.2M
Q1 '232022-12-31-42.1M
Q4 '222022-09-30-83.8M
Q3 '222022-06-30-72.9M
Q2 '222022-03-3141.6M
Q1 '222021-12-31-63.3M
Q4 '212021-09-30-64.9M

Net Income Quarterly

PeriodEndingNet Income
Q3 '262026-06-30-194.3M
Q2 '262026-03-31-132.7M
Q1 '262025-12-3130.8M
Q4 '252025-09-30-23.8M
Q3 '252025-06-30-175.2M
Q2 '252025-03-31370.4M
Q1 '252024-12-31-173.1M
Q4 '242024-09-30-170.5M
Q3 '242024-06-30-170.8M
Q2 '242024-03-31-125.3M
Q1 '242023-12-31-132.9M
Q4 '232023-09-30-109.7M
Q3 '232023-06-30-102.9M
Q2 '232023-03-3148.7M
Q1 '232022-12-31-41.3M
Q4 '222022-09-30-85.5M
Q3 '222022-06-30-72M
Q2 '222022-03-3144.4M
Q1 '222021-12-31-62.9M
Q4 '212021-09-30-63.4M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q3 '262026-06-30-177.5M
Q2 '262026-03-3184.4M
Q1 '262025-12-3113.5M
Q4 '252025-09-3020.5M
Q3 '252025-06-30-154.7M
Q2 '252025-03-31460.1M
Q1 '252024-12-31-146.3M
Q4 '242024-09-30-137.2M
Q3 '242024-06-30-115.4M
Q2 '242024-03-31-92.4M
Q1 '242023-12-31-117.8M
Q4 '232023-09-30-25.9M
Q3 '232023-06-30-20.8M
Q2 '232023-03-31-31.7M
Q1 '232022-12-31-75.5M
Q4 '222022-09-30-68.7M
Q3 '222022-06-30-68.8M
Q2 '222022-03-3162.7M
Q1 '222021-12-31-61.3M
Q4 '212021-09-30-24M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q3 '262026-06-30-181.3M
Q2 '262026-03-3181.9M
Q1 '262025-12-3111.3M
Q4 '252025-09-3013M
Q3 '252025-06-30-157.1M
Q2 '252025-03-31454.8M
Q1 '252024-12-31-153.8M
Q4 '242024-09-30-161.5M
Q3 '242024-06-30-129.9M
Q2 '242024-03-31-126.5M
Q1 '242023-12-31-186.5M
Q4 '232023-09-30-89.8M
Q3 '232023-06-30-67.4M
Q2 '232023-03-31-59M
Q1 '232022-12-31-114.4M
Q4 '222022-09-30-101.4M
Q3 '222022-06-30-78.4M
Q2 '222022-03-3158M
Q1 '222021-12-31-67.1M
Q4 '212021-09-30-32.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q3 '262026-06-30143.4M
Q2 '262026-03-31142.4M
Q1 '262025-12-31140.7M
Q3 '252025-06-30139M
Q2 '252025-03-31134.5M
Q1 '252024-12-31124.8M
Q3 '242024-06-30124.2M
Q2 '242024-03-31123.3M
Q1 '242023-12-31107.4M
Q3 '232023-06-30107M
Q2 '232023-03-31108.1M
Q1 '232022-12-31106M
Q3 '222022-06-30105.8M
Q2 '222022-03-31107.9M
Q1 '222021-12-31104.5M
Q3 '212021-06-30104.1M
Q2 '212021-03-31103.9M
Q1 '212020-12-31102.8M
Q3 '202020-06-30101.8M
Q2 '202020-03-31101.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '262026-06-30-2.18
Q2 '262026-03-31-2.08
Q1 '262025-12-311.60
Q4 '252025-09-30-0.01
Q3 '252025-06-30-1.27
Q2 '252025-03-31-1.39
Q1 '252024-12-31-5.16
Q4 '242024-09-30-5.01
Q3 '242024-06-30-4.66
Q2 '242024-03-31-4.24
Q1 '242023-12-31-2.77
Q4 '232023-09-30-1.92
Q3 '232023-06-30-1.71
Q2 '232023-03-31-1.43
Q1 '232022-12-31-1.47
Q4 '222022-09-30-1.68
Q3 '222022-06-30-1.48
Q2 '222022-03-31-1.09
Q1 '222021-12-31-1.76
Q4 '212021-09-30-1.36